Reports
Published: 2026-02-26 08:00:00
Copenhagen, Denmark, 26 February 2026 - Curasight A/S (TICKER: CURAS), a clinical-stage radiopharmaceutical company pioneering a first-in-class uPAR-targeted radioligand therapy platform addressing multiple aggressive solid tumors, hereby publishes the Year-end report Q4 2025. The Year-end report is available as an attached file to this release and on the Company''s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
"Q4 2025 marked strong momentum, as we advanced the company to become a clinical-stage therapeutic company pioneering uTREAT® - our first-in-class RLT platform targeting uPAR across multiple tumor types. uTREAT® is supported by uTRACE®, our clinically validated uPAR PET diagnostic platform built on the same ligand. uTRACE® enables a true theranostic approach by supporting patient selection, confirming tumor targeting, and de-risking therapeutic development through human imaging validation. We dosed the first patient in our Phase 1 uTREAT® trial in glioblastoma, advancing the program into active clinical development and remaining on track to report top-line data in 2026. uTRACE® continued to progress in the Phase 2 prostate cancer trial and is also on track for top-line data in 2026. With a strengthened balance sheet following DKK 63.4 million in cash and DKK 40 million in new and renegotiated debt facilities, we enter 2026 focused on disciplined execution and delivery of key clinical milestones."
Q4 (2025-10-01 – 2025-12-31)
Q1-Q4 (2025-01-01 – 2025-12-31)
Numbers in parenthesis are the numbers from the same period in 2024.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
E-mail: uk@curasight.com
About Curasight A/S
Curasight is advancing uTREAT®, a clinical-stage, first-in-class uPAR-targeted radioligand therapy (RLT) designed to treat solid tumors. uTREAT® targets uPAR, a key driver of tumor invasion, angiogenesis, and metastasis, which is expressed in more than 85% of solid tumors. The company’s theranostic platform also includes uTRACE®, a uPAR-PET imaging agent built on the same proprietary ligand as uTREAT®. uTRACE® supports patient selection and confirms tumor targeting and has been evaluated in more than 450 patients across nine Phase 2 trials in eight solid tumor indications. The uPAR platform is based on more than a decade of research at the Copenhagen University Hospital and the University of Copenhagen.
